MPM BioVentures 2014, L.P.
CIK: 0001609492
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (42 total)
- Sep 9, 2026TRDA
Entrada Therapeutics, Inc.
Sale(S)Indirect28.8K shares at avg. $7.13$206K - Sep 8, 2026TRDA
Entrada Therapeutics, Inc.
Sale(S)Indirect192.5K shares at avg. $7.41$1.4M - Sep 4, 2026TRDA
Entrada Therapeutics, Inc.
Sale(S)Indirect38.5K shares at avg. $7.11$274K - Sep 3, 2026TRDA
Entrada Therapeutics, Inc.
Sale(S)Indirect32.3K shares at avg. $7.17$231K - Sep 2, 2026TRDA
Entrada Therapeutics, Inc.
Sale(S)Indirect25.1K shares at avg. $7.19$181K - Sep 1, 2026TRDA
Entrada Therapeutics, Inc.
Sale(S)Indirect29.1K shares at avg. $7.06$205K - Aug 26, 2026TRDA
Entrada Therapeutics, Inc.
Sale(S)Indirect14.6K shares at avg. $7.06$103K - Aug 25, 2026TRDA
Entrada Therapeutics, Inc.
Sale(S)Indirect26.5K shares at avg. $7.54$200K - Aug 24, 2026TRDA
Entrada Therapeutics, Inc.
Sale(S)Indirect21.6K shares at avg. $7.34$159K - Dec 4, 2025HOWL
Werewolf Therapeutics, Inc.
Sale(S)Indirect83.2K shares at avg. $0.97$81K - Dec 3, 2025HOWL
Werewolf Therapeutics, Inc.
Sale(S)Indirect57.2K shares at avg. $0.87$50K - Dec 2, 2025HOWL
Werewolf Therapeutics, Inc.
Sale(S)Indirect59.3K shares at avg. $0.89$53K - Dec 1, 2025HOWL
Werewolf Therapeutics, Inc.
Sale(S)Indirect60.9K shares at avg. $0.94$57K - Nov 28, 2025HOWL
Werewolf Therapeutics, Inc.
Sale(S)Indirect20.3K shares at avg. $0.99$20K - Nov 26, 2025HOWL
Werewolf Therapeutics, Inc.
Sale(S)Indirect60.7K shares at avg. $0.98$60K - Nov 25, 2025HOWL
Werewolf Therapeutics, Inc.
Sale(S)Indirect42.5K shares at avg. $0.92$39K - Nov 24, 2025HOWL
Werewolf Therapeutics, Inc.
Sale(S)Indirect88.8K shares at avg. $0.98$87K - Nov 21, 2025HOWL
Werewolf Therapeutics, Inc.
Sale(S)Indirect64.3K shares at avg. $0.83$53K - Nov 20, 2025HOWL
Werewolf Therapeutics, Inc.
Sale(S)Indirect41.2K shares at avg. $0.89$37K - Nov 19, 2025HOWL
Werewolf Therapeutics, Inc.
Sale(S)Indirect66.3K shares at avg. $0.94$62K - Nov 18, 2025HOWL
Werewolf Therapeutics, Inc.
Sale(S)Indirect52.6K shares at avg. $0.93$49K - Nov 17, 2025HOWL
Werewolf Therapeutics, Inc.
Sale(S)Indirect57.1K shares at avg. $0.95$54K - Nov 14, 2025HOWL
Werewolf Therapeutics, Inc.
Sale(S)Indirect61.6K shares at avg. $0.93$57K - Nov 13, 2025HOWL
Werewolf Therapeutics, Inc.
Sale(S)Indirect91K shares at avg. $0.98$89K - Nov 12, 2025HOWL
Werewolf Therapeutics, Inc.
Sale(S)Indirect40.7K shares at avg. $1.09$44K
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Sep 9, 2026 |  TRDA Entrada Therapeutics, Inc. | Sale(S) | 28,837 | $7.13 | $205,608 | Indirect |
| Sep 8, 2026 | TRDA Entrada Therapeutics, Inc. | Sale(S) | 192,500 | $7.41 | $1,426,425 | Indirect |
| Sep 4, 2026 | TRDA Entrada Therapeutics, Inc. | Sale(S) | 38,500 | $7.11 | $273,735 | Indirect |
| Sep 3, 2026 | TRDA Entrada Therapeutics, Inc. | Sale(S) | 32,263 | $7.17 | $231,326 | Indirect |
| Sep 2, 2026 | TRDA Entrada Therapeutics, Inc. | Sale(S) | 25,131 | $7.19 | $180,692 | Indirect |
| Sep 1, 2026 | TRDA Entrada Therapeutics, Inc. | Sale(S) | 29,088 | $7.06 | $205,361 | Indirect |
| Aug 26, 2026 | TRDA Entrada Therapeutics, Inc. | Sale(S) | 14,569 | $7.06 | $102,857 | Indirect |
| Aug 25, 2026 | TRDA Entrada Therapeutics, Inc. | Sale(S) | 26,522 | $7.54 | $199,976 | Indirect |
| Aug 24, 2026 | TRDA Entrada Therapeutics, Inc. | Sale(S) | 21,623 | $7.34 | $158,713 | Indirect |
| Dec 4, 2025 |  HOWL Werewolf Therapeutics, Inc. | Sale(S) | 83,230 | $0.97 | $80,733 | Indirect |
| Dec 3, 2025 | HOWL Werewolf Therapeutics, Inc. | Sale(S) | 57,225 | $0.87 | $49,786 | Indirect |
| Dec 2, 2025 | HOWL Werewolf Therapeutics, Inc. | Sale(S) | 59,277 | $0.89 | $52,757 | Indirect |
| Dec 1, 2025 | HOWL Werewolf Therapeutics, Inc. | Sale(S) | 60,917 | $0.94 | $57,262 | Indirect |
| Nov 28, 2025 | HOWL Werewolf Therapeutics, Inc. | Sale(S) | 20,277 | $0.99 | $20,074 | Indirect |
| Nov 26, 2025 | HOWL Werewolf Therapeutics, Inc. | Sale(S) | 60,733 | $0.98 | $59,518 | Indirect |
| Nov 25, 2025 | HOWL Werewolf Therapeutics, Inc. | Sale(S) | 42,533 | $0.92 | $39,130 | Indirect |
| Nov 24, 2025 | HOWL Werewolf Therapeutics, Inc. | Sale(S) | 88,802 | $0.98 | $87,026 | Indirect |
| Nov 21, 2025 | HOWL Werewolf Therapeutics, Inc. | Sale(S) | 64,331 | $0.83 | $53,395 | Indirect |
| Nov 20, 2025 | HOWL Werewolf Therapeutics, Inc. | Sale(S) | 41,152 | $0.89 | $36,625 | Indirect |
| Nov 19, 2025 | HOWL Werewolf Therapeutics, Inc. | Sale(S) | 66,324 | $0.94 | $62,345 | Indirect |
| Nov 18, 2025 | HOWL Werewolf Therapeutics, Inc. | Sale(S) | 52,627 | $0.93 | $48,943 | Indirect |
| Nov 17, 2025 | HOWL Werewolf Therapeutics, Inc. | Sale(S) | 57,061 | $0.95 | $54,208 | Indirect |
| Nov 14, 2025 | HOWL Werewolf Therapeutics, Inc. | Sale(S) | 61,640 | $0.93 | $57,325 | Indirect |
| Nov 13, 2025 | HOWL Werewolf Therapeutics, Inc. | Sale(S) | 90,951 | $0.98 | $89,132 | Indirect |
| Nov 12, 2025 | HOWL Werewolf Therapeutics, Inc. | Sale(S) | 40,669 | $1.09 | $44,329 | Indirect |
1-25 of 42 transactions
About MPM BioVentures 2014, L.P.
MPM BioVentures 2014, L.P. (SEC CIK 0001609492) files insider reports with the SEC as 10% Owner of Entrada Therapeutics, Inc. (TRDA), 10% Owner of Werewolf Therapeutics, Inc. (HOWL) and iTeos Therapeutics, Inc. (ITOS).
Signal8 holds 15 ownership filings by MPM BioVentures 2014, L.P., all Form 4s, filed between Dec 12, 2024 and Sep 9, 2026. Those filings report 42 transactions, from Dec 10, 2024 to Sep 9, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on MPM BioVentures 2014, L.P.'s filings is in BOSTON, MA.
Recent filings by MPM BioVentures 2014, L.P.
- Sep 9, 2026: Open-market sale of TRDA shares (Form 4, code S).
- Sep 8, 2026: Open-market sale of TRDA shares (Form 4, code S).
- Sep 4, 2026: Open-market sale of TRDA shares (Form 4, code S).
- Sep 3, 2026: Open-market sale of TRDA shares (Form 4, code S).
- Sep 2, 2026: Open-market sale of TRDA shares (Form 4, code S).
Other insiders filing for Entrada Therapeutics, Inc. (TRDA)
- MPM BIOVENTURES 2018, L.P., 10% Owner
- Doshi Dipal, CEO
- Dowden Nathan J, President & COO
- Sethuraman Natarajan, President, Research & Develop.
- WENTWORTH KORY JAMES, Chief Financial Officer
- PARMAR KUSH, Director